FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma By Ogkologos - May 23, 2025 482 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study AK105-304 and Study AK105-202 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy New ESMO Local and Locoregional Prostate Cancer Living Guideline v1.0 MOST POPULAR Durable Responses Observed in Patients with Papillary Craniopharyngiomas Tested Positive for... July 24, 2023 40 K9 Officers Line Up Outside Terminally Ill Girl’s House For... March 26, 2019 For Some Kids with Brain Cancer, Targeted Therapy is Better than... June 29, 2022 Zenocutuzumab Approved to Treat Lung and Pancreatic Cancers with Rare Genetic... March 26, 2025 Load more HOT NEWS How Early Cancer Detection and Diagnosis Saved My Life Twice: A... FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer Experimental Treatment Uses Engineered Fat Cells to “Starve” Tumors What Is Mindfulness and How Can It Help People With Cancer?
